Church of PeptidesSearch
Approved products · Uses differ by product

Tirzepatide

Two signals. A growing assignment.

From a dual-receptor design to diabetes, weight management and sleep-apnea research.

Journey published October 11, 2026 · Evidence reviewed 2026-10-11

Start at the beginning →Where we are today
  1. 01Two stations, one candidateLY3298176 · Published 2018
  2. 02The safety ledger stays openPreclinical efficacy and toxicology
  3. 03Learning the pacePhase 1 and 2 · 2018–2020 publications
  4. 04From glucose to a larger questionSURPASS, SURMOUNT and approvals · 2021–2023
  5. 05The questions do not stop at weightLonger follow-up and sleep apnea · 2023–2025
  6. 06The folder is still growingOctober–November 2026 clinical research and safety notices
Today’s checkpoint

Mounjaro and Zepbound have distinct approved uses. The research now extends beyond glucose and weight; approval never closes the safety record.

Open the medicine’s evidence profile · Other journeys

Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.